View Filing Data

Print Document View Excel Document

Document And Entity Information - shares	6 Months Ended
Document And Entity Information - shares	Jun. 30, 2018	Aug. 13, 2018
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q2
Entity Registrant Name	FENNEC PHARMACEUTICALS INC.
Entity Central Index Key	0001211583
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	FENCF
Entity Common Stock, Shares Outstanding		18,933,242

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 25,640	$ 28,260
Prepaid expenses	60	128
Other current assets	4	13
Total assets	25,704	28,401
Current liabilities:
Accounts payable	709	855
Accrued liabilities	138	622
Derivative instruments (Note 4)	0	167
Total current liabilities	847	1,644
Total liabilities	847	1,644
Stockholders' equity:
Common stock, no par value; unlimited shares authorized; 18,794 shares issued and outstanding (2017-18,411)	104,010	103,045
Additional paid-in capital	45,127	43,837
Accumulated deficit	(125,523)	(121,368)
Accumulated other comprehensive income	1,243	1,243
Total stockholders' equity	24,857	26,757
Total liabilities and stockholders' equity	$ 25,704	$ 28,401

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares shares in Thousands, $ / shares in Thousands	Jun. 30, 2018	Dec. 31, 2017
Common stock, no par value	$ 0	$ 0
Common stock, shares issued	18,794	18,411
Common stock, shares outstanding	18,794	18,411

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Revenue	$ 0	$ 0	$ 0	$ 0
Operating expenses:
Research and development	798	333	1,487	558
General and administrative	1,867	1,146	2,969	1,692
Loss from operations	(2,665)	(1,479)	(4,456)	(2,250)
Other income (expense):
Unrealized gain/(loss) on derivatives (Note 4)	0	(120)	167	(157)
Other loss	5	(4)	2	(5)
Interest income and other	73	5	132	8
Total other income/(expense), net	78	(119)	301	(154)
Net loss	$ (2,587)	$ (1,598)	$ (4,155)	$ (2,404)
Basic net loss per common share	$ (0.14)	$ (0.11)	$ (0.22)	$ (0.17)
Diluted net loss per common share	$ (0.14)	$ (0.11)	$ (0.22)	$ (0.17)
Weighted-average number of common shares outstanding, basic	18,585	14,192	18,508	13,917
Weighted-average number of common shares outstanding, diluted	18,585	14,192	18,508	13,917

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Operating activities:
Net loss	$ (2,587)	$ (1,598)	$ (4,155)	$ (2,404)
Adjustments to reconcile net loss to net cash used in operating activities:
Unrealized loss/(gain) on derivative	0	120	(167)	157
Stock-based compensation - contractors	83	286	197	342
Stock-based compensation - employees	1,207	461	1,381	502
Changes in operating assets and liabilities:
Prepaid assets	47	11	68	22
Other current assets	6	(1)	9	(3)
Accounts payable	(324)	71	(146)	52
Accrued liabilities	(2)	(38)	(484)	(31)
Net cash used in operating activities	(1,570)	(688)	(3,297)	(1,363)
Financing activities:
Short swing profit judgment offset with settlement expense	18	0	18	0
Issuance of units, options and warrants exercised	473	98	659	98
Private placement	0	7,571	0	7,571
Net cash provided by financing activities	491	7,669	677	7,669
(Decrease)/increase in cash and cash equivalents	(1,079)	6,981	(2,620)	6,306
Cash and cash equivalents - Beginning of period	26,719	3,251	28,260	3,926
Cash and cash equivalents - End of period	$ 25,640	$ 10,232	$ 25,640	$ 10,232

Condensed Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income
Balance at Dec. 31, 2017	$ 26,757	$ 103,045	$ 43,837	$ (121,368)	$ 1,243
Balance (in shares) at Dec. 31, 2017		18,411
Stock options issued \| Employees [Member]	174	$ 0	174	0	0
Stock options issued \| Contractors [Member]	114	0	114	0	0
Exercise of stock options	36	$ 71	(35)	0	0
Exercise of stock options (in shares)		23
Exercise of warrants	150	$ 221	(71)	0	0
Exercise of warrants (in shares)		50
Net loss	(1,568)	$ 0	0	(1,568)	0
Balance at Mar. 31, 2018	25,663	$ 103,337	44,019	(122,936)	1,243
Balance (in shares) at Mar. 31, 2018		18,484
Balance at Dec. 31, 2017	26,757	$ 103,045	43,837	(121,368)	1,243
Balance (in shares) at Dec. 31, 2017		18,411
Net loss	(4,155)
Balance at Jun. 30, 2018	24,857	$ 104,010	45,127	(125,523)	1,243
Balance (in shares) at Jun. 30, 2018		18,794
Balance at Mar. 31, 2018	25,663	$ 103,337	44,019	(122,936)	1,243
Balance (in shares) at Mar. 31, 2018		18,484
Short swing profit judgment offset with settlement expense	18	$ 0	18	0	0
Stock options issued \| Employees [Member]	1,207	0	1,207	0	0
Stock options issued \| Contractors [Member]	83	0	83	0	0
Exercise of stock options	$ 35	$ 75	$ (40)	$ 0	$ 0
Exercise of stock options (in shares)		18
Exercise of warrants \| Employees [Member]		$ 598
Exercise of warrants (in shares)	438	292	(160)	0	0
Net loss	$ (2,587)	$ 0	$ 0	$ (2,587)	$ 0
Balance at Jun. 30, 2018	$ 24,857	$ 104,010	$ 45,127	$ (125,523)	$ 1,243
Balance (in shares) at Jun. 30, 2018		18,794

Nature of Business and Going Concern

6 Months Ended

Jun. 30, 2018

Going Concern [Abstract]

Nature of Business and Going Concern

Fennec Pharmaceuticals Inc. (“Fennec”) is a British Columbia corporation. Fennec, together with its wholly-owned subsidiaries Oxiquant, Inc. (“Oxiquant”) and Fennec Pharmaceuticals, Inc., both Delaware corporations, and Cadherin Biomedical Inc. (“CBI”), a Canadian corporation, collectively referred to herein as the “Company,” is a biopharmaceutical company focused on the development of PEDMARK

(a unique formulation of Sodium Thiosulfate (“STS”)) for the prevention of ototoxicity from cisplatin in pediatric patients. With the exception of Fennec Pharmaceuticals, Inc., all subsidiaries are inactive.

These unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) that are applicable to a going concern which contemplates that the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of business.

On June 8, 2017, the Company completed the closing of a non-brokered private placement (the “Offering”) of 1,900,000 common shares for gross proceeds of $7.6 million ($7,571 net of commissions, fees and issue costs). Each common share was issued at a price of $4.00.

On December 12, 2017, the Company announced the completion of an underwritten public offering of 2,352,950 common shares at a public offering price of $8.50 per share. In addition, Fennec issued an additional 135,670 common shares in connection with the partial exercise of the underwriters’ over-allotment option. The approximate total gross proceeds from the offering was $21.2 million ($19,810 net of commissions, fees and issue costs).

During the three and six-months ended June 30, 2018, the Company incurred a loss from operations of $2,665and $4,665, respectively. At June 30, 2018, it had an accumulated deficit of $125.5 million and had experienced negative cash flows from operating activities during the three and six-months ended June 30, 2018 in the amount of $1,570 and $3,297, respectively.

The Company believes the aforementioned raises provide sufficient funding for the Company to carry-out its planned activities for at least the next twelve months as it continues its strategic development of PEDMARK

These financial statements do not reflect the potentially material adjustments in the carrying values of assets and liabilities, the reported expenses, and the balance sheet classifications used, that would be necessary if the going concern assumption were not appropriate.

Significant Accounting Policies

6 Months Ended

Jun. 30, 2018

Accounting Policies [Abstract]

Significant Accounting Policies

Basis of presentation

The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with US GAAP and are the responsibility of the Company’s management. These unaudited interim condensed consolidated financial statements do not include all of the information and notes required by US GAAP for annual financial statements. Accordingly, these unaudited interim condensed consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements and notes filed with the Securities and Exchange Commission (“SEC”) in the Company's Annual Report on Form 10-K for the year ended December 31, 2017. The Company's accounting policies are consistent with those presented in the audited consolidated financial statements included in the Annual Report on Form 10-K for the year ended December 31, 2017. These unaudited interim condensed consolidated financial statements have been prepared in U.S. dollars. All amounts presented are in thousands except for per share amounts.

Use of estimates

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the interim condensed consolidated financial statements and the reported amounts of expense during the reporting period. Actual results could differ from those estimates.

In the opinion of management, these unaudited interim condensed consolidated financial statements include all adjustments, which are normal and recurring in nature, necessary for the fair presentation of the Company’s financial position at June 30, 2018 and to state fairly the results for the periods presented. The most significant estimates utilized during the quarter ended June 30, 2018 included estimates necessary to value grants of stock option to contractors, employees and various contractors, disclosed in Note 5.

New accounting pronouncements 

In June 2018, the FASB issued an accounting pronouncement (FASB ASU 2018-07) to expand the scope of ASC Topic 718, Compensation - Stock Compensation, to include share-based payment transactions for acquiring goods and services from nonemployees. The pronouncement is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2018, with early adoption permitted. We are currently in the process of evaluating the effects of this pronouncement on our consolidated financial statements, including potential early adoption.

In March 2018, the FASB issued ASU 2018-05, "Income Taxes (Topic 740): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118". The overarching purpose of ASU 2018-05 is to codify the guidance issued by the SEC related to income tax accounting implications due to the comprehensive U.S. tax legislation commonly referred to as the Tax Cuts and Jobs Act enacted on December 22, 2017 (the "Tax Reform Act"), as originally discussed within Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (SAB 118) within ASC 740, Income Taxes. SAB 118, and now ASC 740 provide a measurement period, which in no case should extend beyond one year from the Tax Reform Act enactment date, during which a company acting in good faith may complete the accounting for the impacts of the Tax Reform Act. To the extent that a company’s accounting for certain income tax effects of the Tax Reform Act is incomplete, the company can determine a reasonable estimate for those effects and record a provisional estimate in the financial statements in the first reporting period in which a reasonable estimate can be determined. If a company cannot determine a provisional estimate to be included in the financial statements, the company should continue to apply ASC 740 based on the provisions of the tax laws that were in effect immediately prior to the Tax Reform Act being enacted. The Company will continue to analyze the effects of the Tax Reform Act on its Condensed and Consolidated Financial Statements. Additional impacts from the enactment of the Tax Reform Act will be recorded as they are identified during the measurement period as provided for in SAB 118, which extends up to one year from the enactment date.

In February 2017, the FASB issued ASU No. 2017-05, “Other Income - Gains and Losses from the Derecognition of Nonfinancial Assets (Subtopic 610-20): Clarifying the Scope of Asset Derecognition Guidance and Accounting for Partial Sales of Nonfinancial Assets” (“ASU 2017-05”). ASU 2017-05 is meant to clarify the scope of the original guidance within Subtopic 610-20 that was issued in connection with ASU 2014-09, as defined below, which provides guidance for recognizing gains and losses from the transfer of nonfinancial assets in contracts with noncustomers. ASU 2017-05 also added guidance for partial sales of nonfinancial assets. ASU 2017-05 is effective for our fiscal year ending December 31, 2018 and we are required to adopt ASU 2017-05 concurrent with the adoption of ASU 2014-09. The Company adopted ASU 2017-05 January 1, 2018. The Company concluded after evaluation, that the impact of ASU 2017-05 on our consolidated financial statements and disclosures was de minimis.

In May 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update 2017-09,

Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting

(“ASU 2017-09”). The FASB issued ASU 2017-09 to clarify and reduce both (i) diversity in practice and (ii) cost and complexity when applying the guidance in Topic 718, to a change to the terms and conditions of a share-based payment award. This guidance is effective for the Company as of the fourth quarter of its fiscal year ending December 31, 2018. Early adoption is permitted. The amendments in this ASU should be applied prospectively to an award modified on or after the adoption date. The Company is currently evaluating the impact of this updated standard, but does not believe this update will have a significant impact on its consolidated financial statements.

In May 2014, the FASB issued ASU 2014-9, Revenue from Contracts with Customers (Topic 606), to clarify the principles for recognizing revenue. This update provides a comprehensive new revenue recognition model that requires revenue to be recognized in a manner to depict the transfer of goods or services to a customer at an amount that reflects the consideration expected to be received in exchange for those goods or services. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which delayed the effective date of the new standard from January 1, 2017 to January 1, 2018. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations, which clarifies the implementation guidance on principal versus agent considerations. In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, which clarifies certain aspects of identifying performance obligations and licensing implementation guidance. In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients related to disclosures of remaining performance obligations, as well as other amendments to guidance on collectability, non-cash consideration and the presentation of sales and other similar taxes collected from customers. In September 2017, the FASB issued ASU No. 2017-13, Revenue Recognition (Topic 605), Revenue from Contracts with Customers (Topic 606), Leases (Topic 840), and Leases (Topic 842): Amendments to SEC Paragraphs Pursuant to the Staff Announcement at the July 20, 2017 EITF Meeting and Rescission of Prior SEC Staff Announcements and Observer Comments. The amendments in ASU No. 2017-13 amends the early adoption date option for certain companies related to the adoption of ASU No. 2014-09 and ASU No. 2016-02. In November 2017, the FASB issued ASU No. 2017-14, Revenue from Contracts with Customers (Topic 606): Income Statement- Reporting Comprehensive Income (Topic 220), Revenue Recognition (Topic 605), which amends certain SEC paragraphs within the FASB Accounting Standards Codification. These standards had the same effective date and transition date of January 1, 2018. The new revenue standard allows for either full retrospective or modified retrospective application. The Company currently does not have any revenue and therefore this update has virtually no effect on its consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02,

Leases

, which amends the accounting guidance related to leases. These changes, which are designed to increase transparency and comparability among organizations for both lessees and lessors, include, among other things, requiring recognition of lease assets and liabilities on the balance sheet and disclosing key information about leasing arrangements. In September 2017, the FASB issued ASU No. 2017-13, Revenue Recognition (Topic 605), Revenue from Contracts with Customers (Topic 606), Leases (Topic 840), and Leases (Topic 842): Amendments to SEC Paragraphs Pursuant to the Staff Announcement at the July 20, 2017 EITF Meeting and Rescission of Prior SEC Staff Announcements and Observer Comments. The amendments in ASU No. 2017-13 amends the early adoption date option for certain companies related to the adoption of ASU No. 2014-09 and ASU No. 2016-02. Adoption and implementation of the guidance is not required by the Company until the beginning of fiscal 2019, although early adoption is permitted. After completing an assessment of the impact of this ASU, the Company concluded the adoption of this guidance will have virtually no effect on its consolidated financial statements. In July 2018, the FASB issued ASU 2018-10, Codification Improvements to Topic 842 (Leases), which provides narrow amendments to clarify how to apply certain aspects of the new lease standard.

Cash and cash equivalents

Cash equivalents consist of highly liquid investments with original maturities at the date of purchase of three months or less. The Company places its cash and cash equivalents in investments held by highly rated financial institutions in accordance with its investment policy designed to protect the principal investment. At June 30, 2018, the Company had $25,640 in cash and money market accounts ($28,260 at December 31, 2017). At June 30, 2018, the Company held $6,032 in cash of which $80 (as presented in US dollars) was in Canadian dollars ($255 at December 31, 2017 as presented in US dollars). At June 30, 2018, the Company held $19,608 in money market investments. Money market investments typically have minimal risks. The Company has not experienced any loss or write-down of its money market investments since inception.

Earnings per Share

6 Months Ended

Jun. 30, 2018

Earnings Per Share [Abstract]

Earnings Per Share

Earnings per Share

Earnings per common share is presented under two formats: basic earnings per common share and diluted earnings per common share. Basic earnings per common share is computed by dividing net income attributable to common shareholders by the weighted average number of common shares outstanding during the period. Diluted earnings per common share is computed by dividing net income by the weighted average number of common shares outstanding during the period, plus the potentially dilutive impact of common stock equivalents (i.e. stock options and warrants). Dilutive common share equivalents consist of the incremental common shares issuable upon exercise of stock options and warrants. The following table sets forth the computation of basic and diluted net loss per share:

	Three Months Ended June 30,						Six Months Ended June 30,
	2018			2017			2018			2017
Numerator:
Net (loss)	$	(2,587	)	$	(1,598	)	$	(4,155	)	$	(2,404	)

Denominator:
Weighted-average common shares, basic		18,585			14,192			18,508			13,917

Dilutive effect of stock options		-			-			-			-
Dilutive effect of warrants		-			-			-			-
Incremental dilutive shares		-			-			-			-

Weighted-average common shares, diluted		18,585			14,192			18,508			13,917

Net loss per share, basic and diluted	$	(0.14	)	$	(0.11	)	$	(0.22	)	$	(0.17	)

The following outstanding options and warrants were excluded from the computation of basic and diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect:

	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017
Options to purchase common stock		2,579		2,641		2,579		2,641
Warrants to purchase common stock		1,020		1,383		1,020		1,383

Derivative Instruments

6 Months Ended

Jun. 30, 2018

Summary of Derivative Instruments [Abstract]

Derivative Liabilities

Derivative Instruments

As of June 30, 2018, the Company no longer has outstanding derivative instruments. Prior to March 31, 2018, the Company had outstanding options denominated in Canadian dollars which were not considered to be indexed to its own stock because the exercise price is denominated in Canadian dollars and the Company's functional currency is United States dollars. Therefore, these options were treated as derivative financial instruments and recorded at their fair value as a liability. All other outstanding convertible instruments are considered to be indexed to the Company's stock, because their exercise price is denominated in the same currency as the Company's functional currency, and are included in stockholders' equity.

These options were recorded at their fair value as a liability at issuance and were re-measured at fair value as a liability at each subsequent balance sheet date until they were exercised, forfeited or expired. Any change in value between reporting periods was recorded as unrealized gain/(loss). The fair value of these options was estimated using the Black-Scholes option-pricing model.

Comparative data related to gain/(loss) recorded on re-measurement of the derivative liability for the three and six-month periods ended June 30, 2018 and 2017 are summarized in the table below. There is no cash flow impact for these derivatives until the options are exercised. When the options are exercised, the Company receives the proceeds from the exercise at the current exchange rate at the time of exercise.

During the fiscal years ended December 31, 2011 and 2010, the Company issued 36 and 29, respectively, options to contractors with a Canadian dollar denominated strike price. Consequently, the Company had derivatives relating to these options since the strike price is denominated in a currency other than the US dollar functional currency of the Company. While there is an exception to this rule for employees in ASU 2010-13 "Compensation-Stock Compensation (Topic 718): Effect of denominating the exercise price of a share-based payment award in the currency of the market in which the underlying equity security trades", no such exception exists for contractors.

	Three Months Ended June 30,					Six Months Ended June 30,
Gain/(Loss) on Derivative Instruments	2018		2017			2018		2017
Options to contractors	$	-	$	(120	)	$	167	$	(157	)
Gain/(loss) on Derivative Instruments	$	-	$	(120	)	$	167	$	(157	)

The table below summarizes Canadian dollar denominated contractor option activity, during the interim period:

Contractor Options in $CAD	Three Month Period		Six-Month Period			Weighted-Average
Options in Thousands	Ending June 30, 2018					Exercise Price
Opening balance		-		19		$	1.71
Exercised		-		(19	)	$	1.71
Forfeited		-		-		$	-
Expired		-		-		$	-
Ending balance		-		-		$	-

Canadian dollar denominated options issued to contractors vest immediately and are treated as derivative liabilities. In the case a derivative option is exercised, upon the exercise date, the Company extinguishes the derivative liability, records the cash received and the shares issued into common stock and additional paid in capital accordingly. During the three and six-month period ended June 30, 2018, there was an exercise of 0 and 19 Canadian denominated option being treated as derivative liabilities, respectively. This exercise resulted in $0 and $26 gross proceeds to the Company, respectively.

Stockholders' Equity

6 Months Ended

Jun. 30, 2018

Stockholders' Equity Attributable to Parent [Abstract]

Stockholders' Equity

Authorized capital stock

The Company’s authorized capital stock consists of an unlimited number of shares of no par common stock.

Warrants to Purchase Common Stock

The Company has warrants outstanding to purchase common stock priced in U.S. dollars with a weighted average price of $1.50 and a weighted average remaining life of 0.40 years. During the three and six-months ended June 30, 2018, there were 50 and 292 warrants exercised resulting in gross proceeds to the Company of $150 and $438, respectively.

Warrant	Common Shares Issuable Upon Exercise of		Exercise Price
Description	Outstanding Warrants at June 30, 2018		$USD		Expiration Date
Investor warrants		1,020	$	1.50 USD	November 22, 2018
Total		1,020

Stock option plan

The Compensation Committee of the Board of Directors administers the Company’s stock option plan. The Compensation Committee designates eligible participants to be included under the plan and approves the number of options to be granted from time to time under the plan. Currently, the maximum number of option shares issuable is twenty-five percent (25%) of the total number of issued and outstanding shares of common stock. Based upon the current shares outstanding, a maximum of 4,698 options are authorized for issuance under the plan. For all options issued under the plan, the exercise price is the fair value of the underlying shares on the date of grant. All options vest within three years or less and are exercisable for a period of seven years from the date of grant. The stock option plan allows the issuance of Canadian and U.S. dollar grants. The table below outlines recognized contractor and employee expense for the three and six-month periods ended June 30, 2018 and 2017.

	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017
Contractor options expense recognized	$	83	$	286	$	197	$	342
Employee options expense recognized		1,207		461		1,381		502
Total option expense recognized	$	1,290	$	747	$	1,578	$	844

Stock option activity

The following is a summary of option activity for each of the quarterly periods in fiscal year 2018 for stock options denominated in US dollars:

	Number of			Weighted-Average
US Denominated Options	Options (thousands)			Exercise Price $USD
Outstanding December 31, 2017		1,603			2.70
Granted		210			8.38
Exercised		(4	)		2.79
Outstanding at March 31, 2018		1,809			3.36
Granted		95			11.10
Exercised		(7	)		2.72
Outstanding at June 30, 2018		1,897			3.75

During the three-month period ended June 30, 2018, US denominated option exercises provided gross proceeds of $20. US denominated option exercises during the three-month period ended June 30, 2018, resulted in the issuance of 7 common shares. Of the 1,897 options granted and outstanding at June 30, 2018, 2,139 are fully vested and exercisable.

The following is a summary of option activity for the three and six-month periods ended June 30, 2018 for stock options denominated in Canadian dollars:

	Number of			Weighted-Average
Canadian Denominated Options	Options (thousands)			Exercise Price $CAD
Outstanding December 31, 2017		712			2.38
Exercised		(19	)		1.32
Outstanding at March 31, 2018		693			1.86
Exercised		(11	)		1.89
Outstanding at June 30, 2018		682			2.40

For the three and six-month periods ended June 30, 2018, there was no issuance activity related to Canadian dollar denominated options. During the three and six-month periods ended June 30, 2018, there were exercises of 11 and 30 Canadian denominated options, respectively. These exercises resulted in gross proceeds of CAD$21 and CAD$34, respectively $15 and $42 as presented in US dollars, respectively). As of June 30, 2018, all 682 outstanding options denominated in Canadian dollars were fully vested.

Valuation assumptions

The value of options granted were estimated using the Black-Scholes option pricing model using the following assumptions in the table below: The expected volatility was determined using historical volatility of our stock based on the contractual life of the award. There were 95 options issued during the three months ended June 30, 2018, (0 for the same period in 2017). Assumptions for the valuation of the option grants are described in the table below:

	Three Months Ended June 30,
Black-Scholes Model Assumptions	2018			2017
Expected dividend		0.00	%		0.00	%
Risk free rate		2.73 – 2.88	%		2.04 – 2.16	%
Expected volatility		139 - 144	%		133 - 167	%
Expected life		7 years			7 years

Fair Value Measurements

6 Months Ended

Jun. 30, 2018

Fair Value Disclosures [Abstract]

Fair Value Measurements

7.	Fair Value Measurements

The Company adopted the Fair Value Measurements and Disclosure Topic of the FASB in 2011. This Topic applies to certain assets and liabilities that are being measured and reported on a fair value basis. The Topic defines fair value, establishes a framework for measuring fair value in accordance with US GAAP, and expands disclosure about fair value measurements. This Topic enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. The Topic requires that financial assets and liabilities carried at fair value be classified and disclosed in one of the following three categories:

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data.

Level 3: Unobservable inputs that are not corroborated by market data.

	Fair Value Measurement at June 30, 2018
Assets/Liabilities Measured at Fair Value on a Recurring Basis	Quoted Price in Active Markets for Identical Instruments			Significant Other Observable Inputs		Significant Unobservable Inputs
Assets	Level 1			Level 2		Level 3		Total
Cash and cash equivalents	$	6,032	(1)	$	19,608	$	-	$	25,640

(1)

The Company held $6,032 in cash of which $80 (as presented in US dollars) was in Canadian funds.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Commitments and Contingencies

6 Months Ended

Jun. 30, 2018

Commitments and Contingencies Disclosure [Abstract]

Commitments and contingencies

Commitments and Contingencies

Oregon Health & Science University Agreement

On February 20, 2013, Fennec entered into a new exclusive license agreement with OHSU for exclusive worldwide license rights to intellectual property directed to thiol-based compounds, including STS and their use in oncology (the "New OHSU Agreement"). OHSU will receive certain milestone payments, royalty on net sales for licensed products and a royalty on any consideration received from sublicensing of the licensed technology.

The term of the New OHSU Agreement expires on the date of the last to expire claim(s) covered in the patents licensed to Fennec, unless earlier terminated as provided in the agreement. STS is currently protected by methods of use patents that the Company exclusively licensed from OHSU that expire in Europe in 2021 and are currently pending in the United States. The New OHSU Agreement is terminable by either Fennec or OHSU in the event of a material breach of the agreement by either party after 45 days prior written notice. Fennec also has the right to terminate the New OHSU Agreement at any time upon 60 days prior written notice and payment of all fees due to OHSU under the New OHSU Agreement.

On May 18, 2015, Fennec negotiated an amendment ("Amendment 1") to the exclusive license agreement with OHSU. Amendment 1 expands the exclusive license agreement signed with OHSU on February 20, 2013 ("OHSU Agreement") to include the use of N-acetylcysteine as a standalone therapy and/or in combination with STS for the prevention of ototoxicity induced by chemotherapeutic agents to treat cancers. Further, Amendment 1 adjusts select milestone payments entered in the OHSU Agreement including but not limited to the royalty rate on net sales for licensed products, royalty rate from sublicensing of the licensed technology and the fee payable upon the regulatory approval of a licensed product.

Executive Severance

In the event of his termination with us other than for cause, we will be obligated to pay Mr. Raykov a one-time severance payment of $350,000. In the event of his termination with us other than for cause, we will be obligated to pay Mr. Andrade a one-time severance payment of $125,000.

Leases

The Company has an operating lease in Research Triangle Park, North Carolina. This operating lease is terminable with 30 days’ notice and has no penalties or contingent payments due. The Company had rent expense of $1 during the six-month period ended June 30, 2018.

Related Party Transactions

6 Months Ended

Jun. 30, 2018

Related Party Transactions Disclosure

Related Party Transactions

In the second quarter of 2018, the Company recorded approximately $25 related to the net recovery of short-swing profits from one of the Company’s shareholders under Section 16(b) of the Securities Exchange Act of 1934, as amended. The Company recognized these related party proceeds, net of $7 related legal fees and taxes, as an increase to additional paid-in capital in the accompanying interim unaudited condensed consolidated balance sheet as of June 30, 2018 as well as cash proceeds of approximately $18 as cash provided by financing activities in the accompanying interim unaudited condensed consolidated statement of cash flows for quarter ended June 30, 2018.

Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2018

Accounting Policies [Abstract]

Basis of presentation

Use of estimates

New accounting pronouncements

New accounting pronouncements 

In May 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update 2017-09,

Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting

In February 2016, the FASB issued ASU 2016-02,

Leases

Cash and cash equivalents

Earnings per Share (Tables)

6 Months Ended

Jun. 30, 2018

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted

The following table sets forth the computation of basic and diluted net loss per share:

	Three Months Ended June 30,						Six Months Ended June 30,
	2018			2017			2018			2017
Numerator:
Net (loss)	$	(2,587	)	$	(1,598	)	$	(4,155	)	$	(2,404	)

Denominator:
Weighted-average common shares, basic		18,585			14,192			18,508			13,917

Dilutive effect of stock options		-			-			-			-
Dilutive effect of warrants		-			-			-			-
Incremental dilutive shares		-			-			-			-

Weighted-average common shares, diluted		18,585			14,192			18,508			13,917

Net loss per share, basic and diluted	$	(0.14	)	$	(0.11	)	$	(0.22	)	$	(0.17	)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017
Options to purchase common stock		2,579		2,641		2,579		2,641
Warrants to purchase common stock		1,020		1,383		1,020		1,383

Derivative Instruments (Tables)

6 Months Ended

Jun. 30, 2018

Summary of Derivative Instruments [Abstract]

Unrealized Gain on Derivatives

	Three Months Ended June 30,					Six Months Ended June 30,
Gain/(Loss) on Derivative Instruments	2018		2017			2018		2017
Options to contractors	$	-	$	(120	)	$	167	$	(157	)
Gain/(loss) on Derivative Instruments	$	-	$	(120	)	$	167	$	(157	)

Schedule of Other Share-based Compensation, Activity

The table below summarizes Canadian dollar denominated contractor option activity, during the interim period:

Contractor Options in $CAD	Three Month Period		Six-Month Period			Weighted-Average
Options in Thousands	Ending June 30, 2018					Exercise Price
Opening balance		-		19		$	1.71
Exercised		-		(19	)	$	1.71
Forfeited		-		-		$	-
Expired		-		-		$	-
Ending balance		-		-		$	-

Stockholders' Equity (Tables)

6 Months Ended

Jun. 30, 2018

Stockholders' Equity Attributable to Parent [Abstract]

Warrants Outstanding to Purchase Common Stock

Warrant	Common Shares Issuable Upon Exercise of		Exercise Price
Description	Outstanding Warrants at June 30, 2018		$USD		Expiration Date
Investor warrants		1,020	$	1.50 USD	November 22, 2018
Total		1,020

Schedule of Share Based Compensation, Stock Options Expense Recognized

The table below outlines recognized contractor and employee expense for the three and six-month periods ended June 30, 2018 and 2017.

	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017
Contractor options expense recognized	$	83	$	286	$	197	$	342
Employee options expense recognized		1,207		461		1,381		502
Total option expense recognized	$	1,290	$	747	$	1,578	$	844

Schedule of Share-based Compensation, Stock Options, Activity

The following is a summary of option activity for each of the quarterly periods in fiscal year 2018 for stock options denominated in US dollars:

	Number of			Weighted-Average
US Denominated Options	Options (thousands)			Exercise Price $USD
Outstanding December 31, 2017		1,603			2.70
Granted		210			8.38
Exercised		(4	)		2.79
Outstanding at March 31, 2018		1,809			3.36
Granted		95			11.10
Exercised		(7	)		2.72
Outstanding at June 30, 2018		1,897			3.75

The following is a summary of option activity for the three and six-month periods ended June 30, 2018 for stock options denominated in Canadian dollars:

	Number of			Weighted-Average
Canadian Denominated Options	Options (thousands)			Exercise Price $CAD
Outstanding December 31, 2017		712			2.38
Exercised		(19	)		1.32
Outstanding at March 31, 2018		693			1.86
Exercised		(11	)		1.89
Outstanding at June 30, 2018		682			2.40

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions

Assumptions for the valuation of the option grants are described in the table below:

	Three Months Ended June 30,
Black-Scholes Model Assumptions	2018			2017
Expected dividend		0.00	%		0.00	%
Risk free rate		2.73 – 2.88	%		2.04 – 2.16	%
Expected volatility		139 - 144	%		133 - 167	%
Expected life		7 years			7 years

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2018

Fair Value Disclosures [Abstract]

Assets/Liabilities Measured at Fair Value on Recurring Basis

	Fair Value Measurement at June 30, 2018
Assets/Liabilities Measured at Fair Value on a Recurring Basis	Quoted Price in Active Markets for Identical Instruments			Significant Other Observable Inputs		Significant Unobservable Inputs
Assets	Level 1			Level 2		Level 3		Total
Cash and cash equivalents	$	6,032	(1)	$	19,608	$	-	$	25,640

(1)

The Company held $6,032 in cash of which $80 (as presented in US dollars) was in Canadian funds.

Nature of Business and Going Concern - Additional Information (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands			3 Months Ended			6 Months Ended
	Dec. 12, 2017	Jun. 08, 2017	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Going Concern [Line Items]
Net Cash Provided by (Used in) Operating Activities			$ (1,570)		$ (688)	$ (3,297)	$ (1,363)
Retained Earnings (Accumulated Deficit)			(125,523)			(125,523)		$ (121,368)
Net Income (Loss) Attributable to Parent			$ (2,587)	$ (1,568)	$ (1,598)	$ (4,155)	$ (2,404)
Private Placement [Member]
Going Concern [Line Items]
Sale of Stock, Number of Shares Issued in Transaction		1,900,000
Sale of Stock, Price Per Share		$ 4.00
Sale of Stock, Consideration Received on Transaction		$ 7,600
Payments of Stock Issuance Costs		$ 7,571
UnderwrittenPublicOfferingMember [Member]
Going Concern [Line Items]
Sale of Stock, Number of Shares Issued in Transaction	2,352,950
Sale of Stock, Price Per Share	$ 8.50
Sale of Stock, Consideration Received on Transaction	$ 21,200
Payments of Stock Issuance Costs	$ 19,810
Over-Allotment Option [Member]
Going Concern [Line Items]
Sale of Stock, Number of Shares Issued in Transaction	135,670

Significant Accounting Policies - Additional Information (Details) $ in Thousands, $ in Thousands	Jun. 30, 2018 USD ($)	Jun. 30, 2018 CAD ($)	Dec. 31, 2017 USD ($)
Summary Of Significant Accounting Policies [Line Items]
Money market investments	$ 25,640		$ 28,260
Cash		$ 6,032	$ 255
Money Market Funds [Member]
Summary Of Significant Accounting Policies [Line Items]
Money market investments	$ 19,608

Earnings per Share (Schedule of Earnings Per Share, Basic and Diluted) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Numerator:
Net (loss)	$ (2,587)	$ (1,568)	$ (1,598)	$ (4,155)	$ (2,404)
Denominator:
Weighted-average common shares, basic	18,585		14,192	18,508	13,917
Incremental dilutive shares	0		0	0	0
Weighted-average common shares, diluted	18,585		14,192	18,508	13,917
Net loss per share, basic and diluted	$ (0.14)		$ (0.11)	$ (0.22)	$ (0.17)
Warrant [Member]
Denominator:
Dilutive effect	0		0	0	0
Employee Stock Option [Member]
Denominator:
Dilutive effect	0		0	0	0

Earnings per Share (warrants were excluded from the computation of basic and diluted net loss per share) (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,579	2,641	2,579	2,641
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,020	1,383	1,020	1,383

Derivative Instruments (fair value liability) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Gain/(Loss) on Derivative Instruments
Gain/(loss) on Derivative Instruments	$ 0	$ (120)	$ 167	$ (157)
Options [Member]
Gain/(Loss) on Derivative Instruments
Derivative Liability	167	(157)	167	(157)
Gain/(loss) on Derivative Instruments	$ 0	$ (120)	$ 167	$ (157)

Derivative Instruments (Contractor Option Activity) (Details) - $ / shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2018
Stock Options Issuance Outstanding at Beginning	0	19	19
Stock Options Issuance Exercised	0		(19)
Stock Options Issuance Forfeited	0		0
Stock Options Issuance Expired	0		0
Stock Options Issuance Outstanding at Ending	0	0	0
Weighted-average Exercise Price Outstanding at Beginning		$ 1.71	$ 1.71
Weighted-average Exercise Price Exercised			1.71
Weighted-average Exercise Price Forfeited			0
Weighted-average Exercise Price Expired			0
Weighted-average Exercise Price Outstanding at Ending	$ 0		$ 0

Derivative Instruments - Additional Information (Details) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2018	Dec. 31, 2011	Dec. 31, 2010
Derivative [Line Items]
Stock Options Issuance Exercised	0	(19)
Proceeds from Stock Options Exercised	$ 0	$ 26
Canadian Dollar [Member]
Derivative [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number			36	29

Stockholders' Equity (Warrants Outstanding to Purchase Common Stock) (Details) shares in Thousands	6 Months Ended
	Jun. 30, 2018 $ / shares shares
Class of Warrant or Right [Line Items]
Common shares issuable upon exercise of outstanding warrants	1,020
Exercise price in CAD/USD Dollars \| $ / shares	$ 1.50
Inverstor warrants one
Class of Warrant or Right [Line Items]
Common shares issuable upon exercise of outstanding warrants	1,020
Expiration Date	Nov. 22, 2018

Stockholders' Equity (Recognized Contractor and Employee Expense) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Recognized Employee Expense [Line Items]
Stock or Unit Option Plan Expense	$ 1,290	$ 747	$ 1,578	$ 844
Employee Stock Option [Member]
Recognized Employee Expense [Line Items]
Stock or Unit Option Plan Expense	1,207	461	1,381	502
Contractor Option [Member]
Recognized Employee Expense [Line Items]
Stock or Unit Option Plan Expense	$ 83	$ 286	$ 197	$ 342

Stockholders' Equity (Summary of Option Activity) (Details) shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018 $ / shares shares	Mar. 31, 2018 $ / shares shares	Jun. 30, 2018 $ / shares shares	Jun. 30, 2018 $ / shares shares
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Weighted-average Exercise Price Exercised				$ 1.71
Stock Option In Canadian Dollars [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Number of Options Outstanding at Beginning \| shares	693	712	712	712
Number of Options Exercised \| shares	(11)	(19)
Number of Options Outstanding at Ending \| shares	682	693	682	682
Weighted-average Exercise Price outstanding at Beginning	$ 1.86	$ 2.38	$ 2.38
Weighted-average Exercise Price Exercised	1.89	1.32
Weighted-average Exercise Price Outstanding at Ending	$ 2.40	$ 1.86	$ 2.40
Stock Option In Us Dollars [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Number of Options Outstanding at Beginning \| shares	1,809	1,603	1,603	1,603
Number of Options Granted \| shares	95	210
Number of Options Exercised \| shares	(7)	(4)
Number of Options Outstanding at Ending \| shares	1,897	1,809	1,897	1,897
Weighted-average Exercise Price outstanding at Beginning	$ 3.36	$ 2.70	$ 2.70
Weighted-average Exercise Price Granted	11.10	8.38
Weighted-average Exercise Price Exercised	2.72	2.79
Weighted-average Exercise Price Outstanding at Ending	$ 3.75	$ 3.36	$ 3.75

Stockholders' Equity(volatility of our stock based on the contractual life)(Details)	3 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Expected dividend	0.00%	0.00%
Expected life	7 years	7 years
Maximum [Member]
Risk free rate	2.88%	2.16%
Expected volatility	144.00%	167.00%
Minimum [Member]
Risk free rate	2.73%	2.04%
Expected volatility	139.00%	133.00%

Stockholders' Equity - Additional Information (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2017	Jun. 30, 2018	Dec. 31, 2017
Stockholders Equity Note [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.50			$ 1.50
Shares issuable under Stock Option Plan, as percent of shares outstanding				25.00%
Proceeds from Stock Options Exercised	$ 0			$ 26
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	95		0
Stock Issued During Period Shares Stock Warrants Exercised	438
US Denominated [Member]
Stockholders Equity Note [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period				7
Proceeds from Stock Options Exercised	$ 20			$ 20
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	1,897			1,897
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number	2,139			2,139
Canadian Denominated [Member]
Stockholders Equity Note [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	11			30
Proceeds from Stock Options Exercised	$ 21			$ 34
Stock Option In Canadian Dollars [Member]
Stockholders Equity Note [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	11	19
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	682	693		682	712
U.S.dollars [Member]
Stockholders Equity Note [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.50			$ 1.50
Class Or Warrant Or Right Outstanding Weighted Average Remaining Contractual Terms				4 months 24 days
Proceeds from Stock Options Exercised	$ 15			$ 42
Proceeds from Warrant Exercises	$ 150			$ 438
Stock Issued During Period Shares Stock Warrants Exercised	50			292
Maximum [Member]
Stockholders Equity Note [Line Items]
Shares issuable under Stock Option Plan	4,698			4,698

Fair Value Measurements (Assets/Liabilities Measured at Fair Value on Recurring Basis) (Details)
$ in Thousands

Jun. 30, 2018

USD ($)

Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]

Cash and cash equivalents

$ 25,640

Quoted Price in Active Markets for Identical Instruments Level 1 [Member]

Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]

Cash and cash equivalents

6,032

^[1]

Significant Other Observable Inputs Level 2 [Member]

Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]

Cash and cash equivalents

19,608

Significant Unobservable Inputs Level 3 [Member]

Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]

Cash and cash equivalents

$ 0

[1]	The Company held $6,032 in cash of which $80 (as presented in US dollars) was in Canadian funds.

Fair Value Measurements (Assets/Liabilities Measured at Fair Value on Recurring Basis) (Parenthetical) (Details) $ in Thousands, $ in Thousands	Jun. 30, 2018 CAD ($)	Dec. 31, 2017 USD ($)
Assumptions used to Determine Fair Value Options [Line Items]
Cash	$ 6,032	$ 255

Commitments and Contingencies - Additional Information (Details)	6 Months Ended
	Jun. 30, 2018 USD ($)
Operating Leases, Rent Expense	$ 1
Rostislav Raykov
Severance Costs Payable In Case Of Termination Other Than For Cause	350,000
Robert Andrade [Member]
Severance Costs Payable In Case Of Termination Other Than For Cause	$ 125,000

Related Party Transactions - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Proceeds from Short Swing Profit Judgment Offset with Settlement Expense	$ 18	$ 0	$ 18	$ 0
Gross Proceeds from Short Swing Profit Judgment Offset with Settlement Expense			25
Payments for Legal Legal Fees and Taxes			$ 7